NCT02371174View on ClinicalTrials.gov

Post-Marketing Surveillance Study of Eribulin on the Status and Factors for the Development of Peripheral Neuropathy in Japan.

CompletedOBSERVATIONAL

Enrollment

651

Participants

Timeline

Start Date

September 3, 2014

Primary Completion Date

January 21, 2018

Study Completion Date

January 21, 2018

Conditions

Breast CancerHER2-negative Breast Cancer

Trial Locations (2)

Unknown

Osaka

Tokyo

All Listed Sponsors

lead

Eisai Co., Ltd.

INDUSTRY

NCT02371174 - Post-Marketing Surveillance Study of Eribulin on the Status and Factors for the Development of Peripheral Neuropathy in Japan. | Biotech Hunter | Biotech Hunter